Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?

NCT ID NCT07645755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers will test a twice-daily dose in 50 adults who are already taking clopidogrel. The goal is to see if the higher dose provides better protection against clots without increasing bleeding risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AOU Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

    Contact Email: •••••@•••••

    Contact

  • Azienda USL di Pescara - Ospedale Santo Spirito

    Pescara, 65124, Italy

    Contact Email: •••••@•••••

    Contact